next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI)
doravirine (formerly MK-1439) showed potent antiretroviral activity and good
tolerability in combination with tenofovir/FTC (the drugs in Truvada) in a dose-finding study
presented at the 21st Conference on Retroviruses and
Opportunistic Infections (CROI) last week in Boston.
11 March 2014 | Liz Highleyman
oral combination therapy of two antiretroviral drugs, the non-nucleoside
rilpivirine (Edurant, also in Eviplera/Complera) and the new integrase
inhibitor GSK1265744 (744), was at least as effective as a standard nucleosides-plus-efavirenz
triple combination in keeping viral load undetectable in people ...
08 March 2014 | Gus Cairns
Genetically modified CD4 T-cells lacking CCR5 co-receptors reach high
levels in the body and are resistant to HIV infection, potentially enabling
people to maintain a low viral load while off antiretroviral therapy (ART),
according to the latest reports from ...
07 March 2014 | Liz Highleyman
re-emerged in two Boston men who underwent
experimental antiretroviral therapy interruption after receiving bone marrow
stem cell transplants for cancer treatment, Timothy Henrich reported yesterday
at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. These ...
07 March 2014 | Liz Highleyman
Combination therapy using a novel HIV attachment
inhibitor demonstrated good safety and effectiveness, offering the promise of a
new antiretroviral class that may be particularly beneficial for people with
extensive resistance to current drugs, according to a report at ...
06 March 2014 | Liz Highleyman
Two studies in monkeys of an injectable formulation of the third-generation
integrase inhibitor drug GSK1265744 (GSK744LA, where LA stands for ‘long-acting’)
have strengthened the evidence that it may work as pre-exposure prophylaxis
(PrEP) in humans, and a phase II ...
05 March 2014 | Gus Cairns
A short course of
antiretroviral therapy during primary HIV infection (PHI) has immunological and
virological benefits after treatment is stopped, a meta-analysis published in
the online journal PLoS One shows. The benefits of treatment were greatest
for people with lower ...
27 December 2013 | Michael Carter
Almost all HIV-positive people with undetectable
viral load who switched to once-daily raltegravir (Isentress) maintained viral suppression, French researchers
reported at the 14th European AIDS Conference this month in
Brussels. In an effort to facilitate once-daily dosing, Merck is ...
31 October 2013 | Liz Highleyman
The recently approved HIV integrase inhibitor dolutegravir (Tivicay) provides at least equivalent
antiviral efficacy and better tolerability compared with approved
antiretroviral drugs for treatment-naive people, according to data reported at
the 14th European
AIDS Conference last week in Brussels and ...
30 October 2013 | Liz Highleyman
treatment in the coming years will include novel antiretroviral agents and new
formulations such as long-acting injectables, as well as new strategies aimed
at improving adherence and minimising side-effects, it was reported last
week at the 14th
European AIDS Conference ...
22 October 2013 | Liz Highleyman